Abstract

Objective: To demonstrate the potential ofdifferent xanthone derivatives as cyclooxygenase-2 (COX-2) inhibitor agents and their selectivity against cycloooxygenase-1 (COX-1) and COX-2 using molecular simulation.Methods: Nine novel xanthone derivatives (compounds A-I) were employed to dock against protein COX-2 (Protein Data Bank/PDB ID: 1CX2) and COX-1 (PDB ID: 3N8Z). Celecoxib, a selective COX-2 inhibitor, was chosen as a control compound. The free binding energy produced by the docking was scored using Protein-Ligand Ant System (PLANTS) and the hydrogen bonds (H-bonds) between ligands and enzymes were visualised using Pymol.Results: Molecular docking studies revealed that celecoxib docked to the active site of COX-2 enzyme, but not to COX-1; whereasxanthone derivatives docked to the active site of both COX-2 and COX-1. Free binding energy of xanthone derivatives ranged between-73,57 to-79,18 and between-73,06 to-79,25 against COX-2 and COX-1, respectively, and-78,13 against celecoxib. H-bonds in the molecule of xanthone derivatives and COX-2 protein were found in amino acid residues Arg120, Tyr355, Tyr385,and Ser353. There was an insignificant difference between the free binding energyof xanthone derivatives against COX-2 and against COX-1, suggesting that their inhibition was non-selective.Conclusion: In conclusion, in silico studies showed that xanthone derivatives could be effective as potential inhibitors against COX-2, although they are not selective.

Highlights

  • The cyclooxygenase (COX) enzyme plays an important role in the production of prostaglandin from arachidonic acid, which is involved in various processes in the body, including inflammation, pain, and hyperpyrexia [1]

  • COX-1 is a constitutive part of the body thatmaintains the normal function of the gastrointestinal organs, the kidneys, and platelets, while COX-2 is an inducible enzyme that is primarily expressed by various pro-inflammatory cytokines, lipopolysaccharides, mitogens, and oncogens [2]

  • This study aims to investigate the molecular docking of hydroxy-and polyhydroxysubstituted xanthones against COX-1 and COX-2 receptors

Read more

Summary

Introduction

The cyclooxygenase (COX) enzyme plays an important role in the production of prostaglandin from arachidonic acid, which is involved in various processes in the body, including inflammation, pain, and hyperpyrexia [1]. COX-1 is a constitutive part of the body thatmaintains the normal function of the gastrointestinal organs, the kidneys, and platelets, while COX-2 is an inducible enzyme that is primarily expressed by various pro-inflammatory cytokines, lipopolysaccharides, mitogens, and oncogens [2]. COX-2 enzymes are found to be highly expressed in a number of inflammatory processes and tumours, such as inflammatory bowel disease (IBD) and colon cancer, whereas it is minimal or undetected at the normal colon cell [4]. This iswhy research on new anti-inflammatory drugs has been focusing on the identification of compounds with selective activity against COX-2 in preventing the inflammation process

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call